Celltrion Signs 57.6 Billion KRW Supply Contract for Remsima IV with Affiliates
[Asia Economy Reporter Kim Heung-soon] Celltrion announced on the 3rd that it has signed a supply contract for the biosimilar antibody drug Remsima IV worth 57.6 billion KRW with its affiliate Celltrion Healthcare. This accounts for approximately 3.12% of Celltrion's recent sales revenue.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
